Botulinum toxin type A versus anticholinergics for cervical dystonia
Editorial Group: Cochrane Movement Disorders Group
Published Online: 24 JAN 2005
Assessed as up-to-date: 7 OCT 2004
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Costa J, Espírito-Santo CC, Borges AA, Moore P, Ferreira J, Coelho MM, Sampaio C. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004312. DOI: 10.1002/14651858.CD004312.pub2.
- Publication Status: Edited (no change to conclusions)
- Published Online: 24 JAN 2005
Cervical dystonia is the most common form of focal dystonia. It is characterized by involuntary posturing of the head and frequently is associated with neck pain. Disability and social withdrawal are common. Most cases are idiopathic and generally cervical dystonia is a life-long disorder. Botulinum toxin Type A (BtA) is now the first line therapy. Before BtA, anticholinergics were the most widely accepted treatment, so it is important to understand how these two treatments compare.
To compare the clinical efficacy and safety of BtA versus anticholinergic drugs in the treatment of cervical dystonia.
We searched the Cochrane Movement Disorders Group trials register (June 2003), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2003), MEDLINE 1977 to June 2003), EMBASE (1977 to June 2003) and reference lists of articles. We also contacted manufacturers and researchers in the field.
Randomised studies comparing BtA versus any anticholinergic drug for the treatment of cervical dystonia.
Data collection and analysis
Two reviewers independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials.
We found only one trial suitable for inclusion and accordingly no meta-analysis was performed. It compared BtA versus trihexyphenidyl in 66 patients with cervical dystonia. Although this was a relatively small trial with short duration, the results can probably be generalized for the population, since the trial appears to be unbiased and produced clear clinically significant results. The results favoured BtA, and the difference was similar in size to that obtained in a systematic review comparing BtA with placebo. BtA was better tolerated.
The available evidence suggests that BtA injections provide more objective and subjective benefit than trihexyphenidyl to patients with cervical dystonia. We could not draw any conclusions about other anticholinergic drugs. Future trials should explore the role of anticholinergic drugs in patients that do not get benefit with BtA.
Plain language summary
BtA injections provide more objective and subjective benefit than trihexyphenidyl to patients with cervical dystonia.
Cervical dystonia is characterized by involuntary posturing of the head and frequently is associated with neck pain. Disability and social withdrawal are common. Botulinum toxin Type A (BtA) is now the first line therapy but previously anticholinergics were the most widely accepted treatment. This review demonstrated that BtA injections are better than trihexyphenidyl, reduce involuntary muscular movements and tremor, reduce pain, and have fewer adverse effects as measured by objective scales and subjectively by patients.
我們搜尋了the Cochrane Movement Disorders Group trials register (June 2003), the Cochrane Central Register of Controlled Trials(The Cochrane Library Issue 2, 2003), MEDLINE 1977 to June 2003), EMBASE (1977to June 2003)和文章的參考文獻目錄.我們也連絡了製造商和在這個領域的研究員.
此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。